A TYPICAL PATIENT WITH ATRIAL FIBRILLATION AND RENAL DYSFUNCTION - HOW TO PREVENT STROKE?

Aim. To evaluate efficacy and safety of rivaroxaban for stroke and systemicembolism prevention in patients with AF of non-valvular cause and concomitantCKD.Material and methods. Totally 16 patients with AF included, having chronic kidneydisease of II-III stages, who during a year were being assessed an efficacy — casesof death, stroke and systemic embolism, and drug safety (clinically significant andnon-significant bleedings).Results. As a result for efficacy — stroke, systemic embolism, death cases were notregistered. In assessment of safety, mild nasal bleedings (not needed medical help)were marked in 3 patients during one month of treatment, and in 2 patients therewere non-persistent petechias. Clinically significant bleedings were not registered.Conclusion. The usage of the oral anticoagulant rivaroxaban in dose 20 mgand 15 mg per day in patients with AF of non-valvular cause with comorbid CKD II-III stage is effective and safe for the prevention of stroke and systemic embolism.